Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-Outcomes phase 3 trial of oral orforglipron versus placebo for major adverse cardiovascular events
MOH_2025-11-05_015435Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and chronic kidney disease (CKD) comparing Orforglipron with Placebo (2 arms). Primary endpoint: Composite major adverse cardiovascular event endpoint. Started Oct 2025; status: recruiting.
02
Drugs
orforglipron
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2025-11-05_015435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-05_015435.